08:00 , Feb 5, 2015 |  BC Innovations  |  Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
07:00 , Mar 18, 2013 |  BioCentury  |  Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

Anchor Therapeutics, Kyowa Hakko Kirin deal

The companies partnered to use Anchor's pepducin technology to advance Kyowa's GPCR drug discovery portfolio. The partners will also develop pepducin therapeutics and use the pepducin technology to co-develop research tools. Kyowa will be responsible...
08:00 , Jan 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Hematologic malignancies CXC chemokine receptor 4 (CXCR4; NPY3R) In vitro and mouse studies identified cell-penetrating inhibitors of CXCR4 that could help treat hematologic malignancies. In...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Company News

Allegro Diagnostics management update

Allegro Diagnostics Inc. , Boston, Mass.   Business: Diagnostic   Hired: Michael Webb as president, CEO and a director, formerly president and CEO of Anchor Therapeutics Inc.  ...
07:00 , Apr 21, 2011 |  BC Innovations  |  Strategy

A conversation with Gregory Verdine

What will drugs look like in the coming decade? This is the question being posed by Gregory Verdine and the next-generation therapeutic modalities team he leads at Third Rock Ventures . One answer, Verdine believes,...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Anchor Therapeutics, J&J deal

Anchor received an undisclosed cash payment from Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary under a 2010 deal to use Anchor's pepducins technology to discover and develop therapeutics targeting GPCRs for cancer and metabolic disorders....
08:00 , Jan 6, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Hematological mobilization CXC chemokine receptor 4 (CXCR4; NPY3R) Studies in mice and in nonhuman primates suggest that the pepducin-based CXCR4 agonist ATI-2341 could help mobilize...
07:00 , Oct 11, 2010 |  BioCentury  |  Finance

Hallway Chatter

Hallway chatter Companies were busy rolling out their wish lists at the annual BIO Investor Forum in San Francisco last week. Among them was new Executive Chairman Kurt Graves of Intarcia Therapeutics Inc. (formerly BioMedicines...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Company News

Anchor Therapeutics, J&J deal

Anchor partnered with Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary to use Anchor's pepducin technology to discover and develop therapeutics targeting G protein-coupled receptors (GPCRs) for cancer and metabolic disorders. The deal includes Anchor's preclinical...